|Source:||The root of Angelica biserrata (Shan et Yuan) Yuan et Shan.|
|Biological Activity or Inhibitors:||1. Nodakenin has memory-enhancing effect.
2. Nodakenin has anti-aggregatory, and antibacterial activities.
3. Nodakenin has anti-allergic and anti- inflammatory activities, commonly used for the treatment of asthma and chronic bronchitis.
|Solvent:||Pyridine, Methanol, Ethanol, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: firstname.lastname@example.org
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||2.4486 mL||12.2429 mL||24.4858 mL||48.9716 mL||61.2145 mL|
|5 mM||0.4897 mL||2.4486 mL||4.8972 mL||9.7943 mL||12.2429 mL|
|10 mM||0.2449 mL||1.2243 mL||2.4486 mL||4.8972 mL||6.1214 mL|
|50 mM||0.049 mL||0.2449 mL||0.4897 mL||0.9794 mL||1.2243 mL|
|100 mM||0.0245 mL||0.1224 mL||0.2449 mL||0.4897 mL||0.6121 mL|
Biosci Biotechnol Biochem. 2014;78(9):1568-71.
|Effect of nodakenin on atopic dermatitis-like skin lesions.[Pubmed: 25209505]|
|Nodakenin is an important natural resource and medicinal material with anti-allergic and anti- inflammatory activities. We have previously shown that Nodakenin inhibits IgE/Ag-induced degranulation in mast cells. In this study, we investigated the inhibitory effect of Nodakenin on 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis (AD)- like skin lesions in ICR mice. Scratching behavior, skin severity score, blood IgE level, and skin thickness were improved in DNCB-induced AD-like ICR mice. Our results showed that Nodakenin suppressed the increase of AD-like skin lesions in ICR mice. These results suggest that Nodakenin may be a potential therapeutic resource for AD as well as an adjunctive agent to control itching associated with AD.|
Immunopharmacol Immunotoxicol. 2014 Oct;36(5):341-8.
|The effects of nodakenin on airway inflammation, hyper-responsiveness and remodeling in a murine model of allergic asthma.[Pubmed: 25090633]|
|Compared with the model group, Nodakenin treatment markedly inhibited airway inflammation, hyper-responsiveness and remodeling, showing improvement in subepithelial fibrosis, smooth muscle hypertrophy, and goblet cell hyperplasia, and decreased levels of interleukin (IL)-4, IL-5, IL-13 and matrix metalloproteinase-2/-9 in bronchoalveolar lavage fluid, and the level of OVA-specific IgE in serum. In addition, the NF-κB DNA-binding activity in lung tissues was also reduced by Nodakenin treatment.|
J Pharmacol Exp Ther. 2012 Sep;342(3):654-64.
|Nodakenin suppresses lipopolysaccharide-induced inflammatory responses in macrophage cells by inhibiting tumor necrosis factor receptor-associated factor 6 and nuclear factor-κB pathways and protects mice from lethal endotoxin shock.[Pubmed: 22637723]|
|Nodakenin suppressed the transcriptional activity and translocation of nuclear factor-κB (NF-κB) by inhibiting inhibitory κB-α degradation and IκB kinase-α/β phosphorylation. In addition, Nodakenin was found to significantly inhibit the LPS-induced binding of transforming growth factor-β-activated kinase 1 to tumor necrosis factor receptor-associated factor 6 (TRAF6) by reducing TRAF6 ubiquitination. Pretreatment with Nodakenin reduced the serum levels of NO, PGE₂, and proinflammatory cytokines and increased the survival rate of mice with LPS-induced endotoxemia. Taken together, our data suggest that Nodakenin down-regulates the expression of the proinflammatory iNOS, COX-2, TNF-α, IL-6, and IL-1β genes in macrophages by interfering with the activation of TRAF6, thus preventing NF-κB activation.|